DSIP (Delta Sleep-Inducing Peptide)
Cognition, Mood & NeuroprotectionPreclinicalAlso known as: Delta Sleep, Hypnos
Delta sleep-inducing peptide (DSIP) is a nonapeptide — a 9-amino-acid neuropeptide with sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE, 848 Da molecular weight) — first isolated in 1977 from the cerebral venous blood of rabbits subjected to electrical stimulation of the intralaminar thalamus, a brain region involved in sleep regulation. The original Swiss investigators, Schoenenberger and Monnier at the University of Basel, named the peptide for the prominent delta-wave EEG activity they observed in recipient rabbits after intracerebroventricular injection of the purified fraction, implying a role in slow-wave (deep) sleep generation. The name, however, has proven misleading.
Reconstitution Calculator for DSIP (Delta Sleep-Inducing Peptide)
Pre-filled · 2mg vial · 100mcg dose
Overview
At A Glance
Primary Mechanism: Uncharacterized Direct Receptor Binding…
Mechanism of Action
Primary Mechanism: Uncharacterized Direct Receptor Binding
After more than four decades of research, DSIP's primary molecular target remains unknown. No specific receptor has been cloned, characterized, or reproducibly identified as the primary binding site for DSIP. This is a notable feature of the compound — most peptide neuromodulators (oxytocin, vasopressin, CRH, ACTH, etc.) have well-defined G-protein coupled receptors. DSIP does not.
What the pharmacological literature suggests is that DSIP likely works through:
- Modulation of GABAergic transmission: DSIP administration increases GABA release in several brain regions and appears to potentiate GABA-A receptor function indirectly. This may account for its sleep-promoting and anxiolytic effects (Graf & Kastin, 1984).
- Interaction with adrenergic systems: DSIP reduces noradrenergic outflow in stress paradigms and may modulate locus coeruleus activity, consistent with the observed stress-reducing and sleep-promoting effects.
- Opioid system modulation: DSIP potentiates endogenous opioid activity in some assays and may work partially through enkephalin/endorphin release. This is consistent with its reported use in opioid withdrawal and chronic pain.
- Hypothalamic-pituitary axis effects: DSIP influences release of growth hormone, luteinizing hormone, and ACTH in various experimental contexts, suggesting central hypothalamic action. These effects are inconsistent across studies.
- Direct membrane effects: Some evidence suggests DSIP may stabilize neuronal membranes and modulate calcium channel function independent of classical receptor-mediated signaling (Schoenenberger, 1984).
EEG and Sleep Architecture Effects
The original rabbit experiments showed strong delta-wave generation after DSIP administration. Human studies have been more modest and variable:
- Increased total sleep time: Modest increases (5-15%) reported in some chronic insomnia studies (Schneider-Helmert, 1984).
- Reduced sleep latency: Time to sleep onset may be reduced 10-20 minutes in responders.
- Slow-wave sleep (SWS) changes: Variable — some studies show increased SWS percentage, others show no change or even decreases.
- REM sleep effects: Generally unchanged or mildly increased; DSIP does not appear to suppress REM the way benzodiazepines do.
- Subjective sleep quality: Generally positive reports from responders; no effect in non-responders. Response appears bimodal.
Critically, many of these effects in human studies are statistically small and do not approach the magnitude suggested by the compound's name or marketing. A meta-analysis of available DSIP sleep trials has never been conducted (there are too few trials with varied methodology), but the available data would not support a strong sleep-promotion claim comparable to benzodiazepines or z-drugs.
Stress and HPA Axis Effects
More consistent than the sleep data are the stress-modulating effects. DSIP administration in animal models and some human studies reduces cortisol response to stress, blunts adrenergic activation, and produces a subjective sense of calm without sedation. This is consistent with:
- Inhibition of CRH release from the hypothalamus
- Dampening of sympathetic nervous system activation
- Possible direct actions on amygdala or related limbic structures
- Elevation of endogenous opioid tone
This stress-modulating effect, rather than direct sleep induction, may account for some of the subjective sleep improvements users report — better sleep often follows from reduced stress and anxiety at bedtime.
Pain Modulation
DSIP shows analgesic activity in animal pain models and has been studied in humans for chronic pain syndromes, particularly in Russian and Eastern European literature. Mechanisms likely involve:
- Endogenous opioid system potentiation
- GABAergic modulation in spinal cord and brain stem
- Possible direct effects on descending pain pathways
- Anti-stress effects reducing the affective dimension of pain
Clinical use for chronic pain has been reported but with generally weak methodology. Evidence quality is not comparable to standard pain pharmacotherapy.
Pharmacokinetics and Delivery
DSIP is a small peptide (9 amino acids, 848 Da) that undergoes rapid enzymatic degradation in plasma and peripheral tissues. Observed plasma half-life after intravenous administration is extraordinarily short — approximately 7-15 minutes — meaning the intact peptide is cleared from circulation rapidly. Despite this, clinical effects often outlast plasma exposure, suggesting either:
- Metabolite activity (breakdown products may have their own activity)
- Rapid CNS penetration during the brief plasma window
- Downstream cascade effects that outlast the direct peptide presence
- Receptor-mediated events that cascade beyond acute exposure
Typical delivery routes:
- Subcutaneous injection: Most common; injectable vials typically reconstituted in bacteriostatic water. 100-300 mcg doses common.
- Intranasal spray: Increasingly popular; bypasses first-pass metabolism, may improve CNS delivery. 100-500 mcg doses common.
- Intravenous: Historically used in research; not practical for home use.
- Sublingual: Used but absorption is poor for peptides; bioavailability questionable.
- Oral capsules: Essentially ineffective due to GI degradation.
Blood-Brain Barrier Penetration
DSIP was named with the assumption it crosses the blood-brain barrier (BBB), and early animal studies supported this. However, more recent work questions the magnitude of BBB penetration — DSIP is hydrophilic and small, but the relevant transport mechanisms are not well-characterized. Intranasal delivery may provide superior CNS access by bypassing the BBB entirely via the olfactory pathway, which is one rationale for the popularity of nasal spray formulations.
Off-Target Activity
Because the primary receptor is unknown, off-target activity is difficult to characterize. DSIP has been screened against numerous classical receptors (opioid, GABA, serotonin, dopamine, etc.) without clean binding at any single site. This is consistent with either (1) a novel receptor not yet characterized, or (2) modulation of multiple systems indirectly without direct receptor binding, or (3) a physiologically active peptide whose primary function is regulatory rather than signal-transducing in a classical sense.
Endogenous DSIP
DSIP-like immunoreactivity has been detected in human plasma, CSF, and brain tissue, and appears to vary with sleep-wake state and stress. Endogenous DSIP concentrations are very low (picomolar range), which is typical of peptide neuromodulators. Whether exogenous DSIP supplementation at the much higher pharmacological doses used clinically (~100-500 mcg subcutaneous = very high supra-physiological levels) produces effects analogous to endogenous function or simply pharmacological activity is unclear.
Overview
Delta sleep-inducing peptide (DSIP) is a nonapeptide — a 9-amino-acid neuropeptide with sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE, 848 Da molecular weight) — first isolated in 1977 from the cerebral venous blood of rabbits subjected to electrical stimulation of the intralaminar thalamus, a brain region involved in sleep regulation. The original Swiss investigators, Schoenenberger and Monnier at the University of Basel, named the peptide for the prominent delta-wave EEG activity they observed in recipient rabbits after intracerebroventricular injection of the purified fraction, implying a role in slow-wave (deep) sleep generation.
The name, however, has proven misleading. Four decades of follow-up research have produced a pharmacological profile that is substantially more complex than "sleep peptide" — and, depending on how generously you interpret the human clinical data, somewhat less impressive than the name suggests. DSIP does not reliably produce the dramatic delta-wave surges in humans that it appeared to produce in the original rabbit EEG studies. It does, however, demonstrate real effects on sleep architecture, stress response, pain modulation, and possibly mood regulation, and it has been studied (primarily in Russian, Eastern European, and Japanese clinical literature from the 1980s-1990s) for chronic insomnia, chronic pain syndromes, alcohol and opioid withdrawal, depression, and as an adjunct to conventional sleep and anxiolytic medications.
Despite 40+ years of research, DSIP has never been approved by the FDA, EMA, or any major regulatory agency for any indication. It circulates today almost exclusively through the research chemical peptide market, where it is sold as subcutaneous injection vials, nasal spray formulations, and occasionally as sublingual preparations. Users report highly variable effects — some describe profound sleep improvements from a single bedtime injection, others notice nothing at all, and a subset report vivid dreams or morning "grogginess" that can last into the next day. The compound's reputation in the biohacking community is of a "safe, non-addictive, mild-effect sleep aid" positioned as a cleaner alternative to benzodiazepines, z-drugs (zolpidem, eszopiclone), and chronic melatonin. Whether it actually deserves that reputation depends substantially on what clinical claims you are willing to accept on thin evidence.
This entry covers what is genuinely established about DSIP pharmacology, what the clinical trial record actually shows (versus what marketing claims), how it is used in practice by peptide practitioners, safety considerations, and honest framing of the evidence gaps. It should be read as an educational reference, not a prescription — DSIP is not FDA-approved, is distributed through gray-market channels of variable quality, and any serious use decision should involve a qualified physician familiar with research peptides, appropriate sleep-hygiene tuning first, and realistic expectations. Cross-reference this page with Semax, Selank, and Epitalon for a complete picture of the Russian-origin "research peptide" landscape, and with BPC-157 and Tesamorelin for more thoroughly characterized peptide therapeutics.
Potential Research Fields
Chemical Information
IUPAC Name
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
CAS Number
62568-57-4
Molecular Formula
C35H48N10O15
Molecular Mass
848.81 g/mol
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Interaction Matrix
Contraindications
Absolute Contraindications
DSIP must NOT be used in the following circumstances:
- Known allergy or hypersensitivity to DSIP or components — rare but possible with any peptide
- Pregnancy — insufficient safety data; peptide modulation of sleep/stress axes not evaluated in pregnancy
- Lactation — insufficient safety data
- Severe underlying respiratory disease with hypercapnia — any sleep-affecting intervention requires caution; untreated or poorly-controlled sleep apnea is a specific concern (see below)
- Acute intoxication with sedative substances — combining DSIP with acute alcohol, benzodiazepine, opioid overdose is additive CNS depression
- Untreated moderate-severe obstructive sleep apnea — DSIP does not cause apnea but deeper sleep may exacerbate it; treat the apnea (CPAP, oral appliance, surgery) first
Relative Contraindications / Caution Warranted
- Pediatric and adolescent use: No safety data; peptide modulation of developing neurology unknown; not recommended
- Elderly with cognitive impairment: Baseline cognitive evaluation; start with lowest doses; monitor for confusion or gait changes
- History of complex sleep behaviors: Rare with DSIP but any sleep-affecting compound warrants attention
- Severe depression: Treat underlying depression; DSIP is not an antidepressant
- Active substance use disorder: Overall addiction-neutral but behavioral patterns around sleep aids merit attention
- Unstable mental health conditions: Psychiatric evaluation before starting any sleep-affecting compound
- Severe renal or hepatic impairment: Peptide clearance may be altered; limited data
- Active seizure disorder: No clear interaction but any CNS-affecting compound requires caution; discuss with neurologist
- Concurrent heavy alcohol use: Additive sedation possible; alcohol itself disrupts sleep architecture
- Occupational safety considerations: Next-day alertness should be verified before operating vehicles or equipment
Specific Drug Interactions
Limited formal interaction studies exist for DSIP. The following concerns are extrapolated from pharmacology:
- Benzodiazepines (alprazolam, lorazepam, diazepam, etc.): Additive CNS depression possible; reduce BZD dose if combining; ideally avoid routine combination
- Z-drugs (zolpidem, eszopiclone, zaleplon): Similar concerns; consider one or the other, not both
- Opioids (morphine, oxycodone, hydrocodone, etc.): Theoretical potentiation via endogenous opioid modulation; caution in opioid-treated patients
- Sedating antidepressants (trazodone, mirtazapine, doxepin): Additive sedation possible; usually manageable
- Sedating antihistamines (diphenhydramine, doxylamine): Often redundant; pick one or the other
- Alcohol: Additive CNS depression; avoid combining
- Muscle relaxants (cyclobenzaprine, carisoprodol): Additive sedation
- Gabapentin/pregabalin: Generally no concerning interaction; often used together
- SSRIs/SNRIs: No clear concern; DSIP may be modestly helpful alongside SSRIs for SSRI-induced insomnia
- Lithium: No known interaction; caution as always
- Melatonin: Often combined; low-dose melatonin preferred
- Magnesium: Synergistic and safe combination
- Stimulants (caffeine, amphetamines, modafinil): Opposing effects; timing separation more important than absolute avoidance
- Blood pressure medications: No significant interaction; DSIP may have mild hypotensive effects
Interactions with Other Research Peptides
- CJC-1295, Ipamorelin, Tesamorelin: Often combined in evening stack; generally safe and potentially synergistic
- Selank: No concerning interaction; sometimes stacked for stress/sleep axis
- Semax: Semax is stimulating; time-separate from DSIP (Semax morning, DSIP evening)
- Epitalon: Often combined for circadian/pineal support
- BPC-157, TB-500: No concerning interaction; different mechanisms
Pre-Use Considerations
Before starting DSIP, consider:
- Is sleep hygiene optimized? No peptide replaces good sleep hygiene. If your bedroom has TV, phone usage continues to bedtime, or schedule is irregular, fix those first.
- Have underlying conditions been evaluated? Sleep apnea, restless legs, untreated depression/anxiety, thyroid dysfunction are all more impactful than DSIP can address.
- Have simpler agents been tried? Magnesium, glycine, L-theanine, apigenin, low-dose melatonin all have better evidence than DSIP and work for many people.
- Is this for genuine insomnia or anticipatory use? People with adequate sleep often don't benefit from sleep aids and may develop psychological dependence.
- What's the source? Gray-market peptide quality varies; investigate supplier.
- Is the budget appropriate for the marginal benefit? DSIP is often not the most cost-effective sleep intervention.
Monitoring for Adverse Response
- Unusual morning sedation persisting past 1-2 hours
- Worsening rather than improving sleep
- New onset mood changes, depression, or anxiety
- Vivid dreams severe enough to disrupt sleep
- Any allergic-type reaction (hives, swelling, breathing difficulty)
- Injection site reactions beyond mild redness
Any of these warrants reduction, discontinuation, or medical evaluation.
Pregnancy, Lactation, Fertility
No human data. Peptide neuromodulators theoretically could affect developing neurology. Avoid during conception efforts, pregnancy, and lactation.
Pediatric Use
Not indicated. Pediatric sleep disorders require specialist evaluation and age-appropriate interventions.
Driving and Machinery
Assess your individual next-day alertness before driving or operating machinery after DSIP use. Most users feel normal by morning, but this is individual. Start with days when you don't have safety-critical activities the next day.
Competitive Athletics
DSIP is not on the World Anti-Doping Agency (WADA) prohibited list as of current reference, but regulations change. Any competitive athlete should verify current status with their sport's governing body. Research peptides in general are under increasing scrutiny.
Long-Term Use Philosophy
While DSIP appears safe long-term based on limited data, the spirit of good pharmacology is to use the minimum for the shortest duration that achieves the goal. Indefinite nightly DSIP use, even if apparently safe, reflects a suboptimal situation — either underlying sleep issues haven't been addressed, or psychological dependence on a sleep aid has developed. Intermittent use and periodic breaks are wise.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
$29.00
up to $60.00
$4.5000
7
10
vial, strip, spray
| Vendor | Product | Form | Qty | Price | $/mg | Coupon | |
|---|---|---|---|---|---|---|---|
 |
DSIP 5mg | vial | 1 vial● Out of Stock | $29.00BEST | $5.800 | — | Sign in for stock alert |
|
|
DSIP 10mg | vial | 1 vial● In Stock | $45.00VALUE | $4.500 | — | |
| Counting Sheep Spray | spray | 0mg● In Stock | $55.00 | — | |||
| REM Spray | spray | 0mg● In Stock | $60.00 | — | |||
 |
DSIP 5mg | vial | 1 vial● In Stock | $34.99 | $6.998 | — | |
|
|
DSIP 5mg | vial | 1 vial● In Stock | $34.99 | $6.998 | — | |
 |
DSIP 5mg Vial | vial | 1 vial● In Stock | $35.00 | $7.000 | ||
 |
DSIP 5mg | vial | 1 vial● Out of Stock | $32.00 | $6.400 | Sign in for stock alert | |
 |
DSIP 5mg | vial | 5mg vial● In Stock | $34.99 | $6.998 | ||
| Nighttime Dissolving Strips | strip | 1 pack● In Stock | $29.99 | $5.998 | — |
Tracking since Mar 13, 2026 · 8 data points
Price History
6 data pointsVendors Selling DSIP (Delta Sleep-Inducing Peptide)
Ion Peptide
GetMelts
Limitless Biochem EU
BioMyst Labs
VANDL Labs
Nova Peptides
Adera
How we score these vendors
Every supplier above is graded 0–100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank.
Research Score
518 PubMed studies
Quality Indicators
Data Completeness
100%Research Credibility
Well-researched compound
Quick Facts
Half-Life
~7–8 minutes IV (short, but sleep-promoting effects last hours)
Molecular Weight
848.81 g/mol
Administration
Subcutaneous, Intramuscular, Intranasal
CAS Number
62568-57-4
Trial Phase
Preclinical
Safety Profile
Low RiskCommon Side Effects
- • Morning grogginess (high doses)
- • Vivid dreams
- • Mild headache
Stop Use If
- Insufficient data for pregnancy/breastfeeding
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Does DSIP actually work for sleep?
DSIP produces modest, inconsistent sleep benefits in humans — nothing like what the name 'delta sleep-inducing peptide' implies. Roughly 30-40% of users notice clear sleep improvement, 30-40% notice partial benefit, and 20-40% see no effect. The clinical trial evidence (Schneider-Helmert, 1984) supports small improvements in sleep latency and subjective quality, not dramatic sedation. If you're looking for benzodiazepine-level sleep induction, DSIP will disappoint. If you want a mild, non-habit-forming assist alongside good sleep hygiene, it can be reasonable.
Is DSIP FDA-approved?
No. DSIP has never been FDA-approved for any indication. It was discovered in 1977 and has been studied for 40+ years, but never completed the large, well-powered Phase 3 trials that modern regulatory approval requires. It circulates exclusively through research chemical peptide suppliers as a 'for research use only' compound, with no FDA oversight of manufacturing or use. Product quality varies significantly across suppliers.
What's the typical starting dose?
For sleep support, 100 mcg subcutaneously 30-60 minutes before bed is a conservative starting dose. Most users titrate to 200 mcg as a maintenance dose. Doses above 300 mcg don't produce proportionally more sleep benefit and increase the likelihood of morning grogginess and vivid dreams. Intranasal products typically deliver 100-200 mcg per dose depending on formulation; verify product specifications before dosing.
How do I tell if DSIP is working?
Track before starting: sleep latency (time to fall asleep), total sleep time, subjective quality (1-10 scale), morning alertness. Track 1-2 weeks of baseline, then 2-4 weeks on DSIP. Consumer devices (Oura, Whoop, Apple Watch) provide useful objective context. A 'working' result typically looks like 10-20 minute faster sleep onset, 1-2 point subjective quality improvement, and maintained or improved morning alertness. If you see nothing after 4 weeks at 200 mcg, you're likely a non-responder.
Can DSIP be used nightly indefinitely?
Probably safe based on limited data, but not ideal practice. DSIP shows no known dependence, tolerance, or withdrawal syndromes. However, long-term safety data is genuinely limited — most trials were weeks, not years. Prudent practice is intermittent use (5 nights on, 2 off; or 3-4 nights per week) with periodic breaks (2-4 weeks off every 3-6 months) to avoid any theoretical tolerance and maintain clarity about ongoing need.
How does DSIP compare to melatonin?
Different mechanisms and roles. Melatonin is a circadian signaling hormone — at low doses (0.3-0.5 mg) it anchors your body's clock; at high doses (3-10 mg) it becomes more of a sedative with side effects (vivid dreams, morning hangover). DSIP doesn't directly signal circadian timing; it modulates sleep architecture and stress response with an uncharacterized mechanism. Low-dose melatonin + DSIP can be synergistic — melatonin for timing, DSIP for depth. High-dose melatonin alone is often less effective than low-dose melatonin + sleep hygiene.
What are the main side effects?
Most common: next-morning grogginess at higher doses (5-15%), vivid dreams (5-10%), mild injection site reactions for SC users (5-10%), mild nasal irritation for intranasal users. Uncommon: headache, dizziness, mild mood changes. Rarely, paradoxical sleep disruption in some users. Not reported: dependence, tolerance, withdrawal, cognitive impairment, respiratory depression, complex sleep behaviors. Overall DSIP has one of the cleanest safety profiles in the peptide space, though long-term data is limited.
Can I take DSIP with other sleep aids?
Yes, thoughtfully. Safe and commonly-stacked combinations: magnesium glycinate, glycine, L-theanine, apigenin, low-dose melatonin (0.3-0.5 mg). Use caution with additive sedatives: benzodiazepines, z-drugs, sedating antihistamines, alcohol — these can produce oversedation. Generally avoid routinely combining pharmaceutical hypnotics (zolpidem, etc.) with DSIP unless specifically advised; instead use DSIP as a tool to potentially reduce or taper pharmaceutical sleep aids.
Why is DSIP sold as a research chemical rather than a regulated medication?
Primarily commercial: DSIP is a naturally-occurring peptide, cannot be patented, and no company could profitably develop it through expensive Phase 3 trials. It fell into the gray market because its evidence base — while suggestive — never crossed the threshold for regulatory approval. Additionally, the pharmaceutical industry has focused on small-molecule sleep agents (z-drugs, orexin antagonists) with patent protection and easier manufacturing. The result is that DSIP exists in a research chemical space without formal regulatory oversight despite decades of study.
Should I choose injection or nasal spray?
Both work; most experienced users prefer subcutaneous injection. Injection: more precise dosing, more reliable absorption, slightly stronger effect in most users, requires injection skills. Nasal spray: easier to use, no needles, possibly less pronounced effect, dose consistency can vary by technique. Start with whichever fits your preferences and lifestyle. Many users prefer injection for consistency and dose precision, reserving nasal spray for travel or occasional use when injections are inconvenient.
Research Tools
Side-by-Side Comparisons
All ComparisonsCompare DSIP (Delta Sleep-Inducing Peptide) head-to-head: mechanism, half-life, dosing, safety, and live pricing.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.